Tango Therapeutics
2 known investors
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors. The company focuses on expanding access to precision cancer therapies for patients.
Biotech
Investors · 2
In the news
- Mizuho raises Tango Therapeutics stock price target on combo data By Investing.cominvesting.com · 2026
- JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.comng.investing.com · 2026
- Tango Therapeutics (TNGX) Enters Russell Growth Indexes and Adds Biopharma Veteran Azelby to Board - Simply Wall St Newssimplywall.st · 2026
- Tango Therapeutics (TNGX) Could Be 64% Below Fair Value As It Adds Robert Azelby - Simply Wall St Newssimplywall.st · 2026
- Jefferies Upgrades Tango Therapeutics to Buy From Hold, Price Target is $27 | MarketScreenermarketscreener.com · 2026